IMR Press / JIN / Volume 21 / Issue 5 / DOI: 10.31083/j.jin2105144
Open Access Review
BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression
Show Less
1 Department of Biomedical Sciences, University of Cagliari, 09042 Cagliari, Italy
*Correspondence: ecarboni@unica.it (Ezio Carboni)
Academic Editor: Robert Friedman
J. Integr. Neurosci. 2022, 21(5), 144; https://doi.org/10.31083/j.jin2105144
Submitted: 30 April 2022 | Revised: 16 June 2022 | Accepted: 17 June 2022 | Published: 16 August 2022
(This article belongs to the Special Issue Structure and Organization of Neural Systems in Animals)
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Major depressive disorder is one of the primary causes of disability and disease worldwide. The therapy of depression is prevalently based on monoamine reuptake blockers; consequently, investigations aimed to clarify the aetiology of depression have mostly looked at brain areas innervated by monamines and brain circuitry involved in inputs and outputs of these areas. The recent approval of esketamine as a rapid-acting antidepressant drug in treatment-resistant depression, has definitively projected glutamatergic transmission as a key constituent in the use of new drugs in antidepressant therapy. In this review we have examined the role of several brain areas: namely, the hippocampus, the medial Prefrontal Cortex (mPFC), the nucleus accumbens (NAc), the Lateral Habenula (LHb), the amygdala and the Bed Nucleus of Stria Terminalis (BNST). The reason for undertaking an in-depth review is due to their significant role in animal models of depression, which highlight their inter-connections as well as their inputs and outputs. In particular, we examined the modification of the expression and release of the brain derived neurotrophic factor (BDNF) and associated changes in dendritic density induced by chronic stress in the above areas of animal models of depression (AnMD). We also examined the effectiveness of ketamine and standard antidepressants in reversing these alterations, with the aim of identifying a brain circuit where pathological alteration might trigger the appearance of depression symptoms. Based on the role that these brain areas play in the generation of the symptoms of depression, we assumed that the mPFC, the NAc/Ventral Tegmental Area (VTA) and the hippocampus form a primary circuit of depression, where regular performance can endure resilience to stress. We have also examined how this circuit is affected by environmental challenges and how the activation of one or more areas, including amygdala, LHb or BNST can produce local detrimental effects that spread over specific circuits and generate depression symptoms. Furthermore, we also examined how, through their outputs, these three areas can negatively influence the NAc/VTA-PFC circuit directly or through the BNST, to generate anhedonia, one of the most devastating symptoms of depression.

Keywords
depression
ketamine
BDNF
prefrontal cortex
hippocampus
nucleus accumbens
lateral habenula
amygdala
bed nucleus of stria terminalis
1. Introduction
1.1 Depression

Depression is a complex pathology, in terms both of its aetiology and symptomatology. Although the aetiology of depression is still undefined, it is widely accepted that it is likely to emerge from the interaction of genetic and epigenetic factors [1]. Symptoms of primary relevance include a marked diminished interest or pleasure in most or all activities, the feeling of worthlessness or inappropriate guilt, and recurrent suicidal ideation or attempts [2]. Although these symptoms are hardly reproducible in animal models of depression (AnMD), the evaluation of peculiar behavioural features in rodents have markedly contributed to the preclinical development of many antidepressants [3], but the limits of AnMD in terms of predictive, face, construct and translation validity [4, 5], have limited the progress in understanding the role of specific brain areas in the aetiology of depression. Despite this, the objective morphological and biochemical changes that have been observed in specific brain areas of patients and AnMD (i.e., hippocampal neurogenesis and Brain Derived Neurotrophic Factor (BDNF) expression and release) have allowed researchers to consider the function of these areas as crucial in depression onset and in therapeutic response. In addition, other brain areas are thought to be involved in depression because they support certain functions that are lost in depression, leading to the onset of relevant symptomatology. Moreover, future attempts and attempts made thus far to characterize the brain circuits that are involved in depression can benefit from the identification of the sites of binding and the mechanism of action of antidepressants.

1.2 Antidepressants

It has been estimated that, even when they are sufficiently treated for Major Depressive Disorder (MDD), more than one-third of patients do not respond to first line Standard Antidepressant (StAD) treatment for reasons that have not yet been clarified [6, 7]. The search for effective and well-tolerated new antidepressants is clearly an urgent need. At the moment, the development of new antidepressants can be pursued predominantly through testing their effects in AnMD [8]; the next phase of development and an essential intermediate goal in this process will entail acquiring a better understanding of brain circuits underlying antidepressant behavioural response in rodents.

1.3 Ketamine

Among recently produced antidepressants, ketamine stands out for its effects, although its precise mechanism of action has not yet been clarified [9, 10]. Ketamine is an anaesthetic and analgesic drug [11, 12] and possesses dissociative properties that have prompted its use as a recreational drug of abuse, mostly among adolescents [13]. Many years of investigations into the involvement of glutamatergic transmission in depression [14] have led to the discovery of the rapid and sustained antidepressant properties of ketamine [15]. The relevance of this finding is that the antidepressant effects of ketamine do not require 2–3 weeks of treatment to emerge, as is the case with StAD; indeed, many investigations have shown that the reduction of depression symptoms can be observed within 48–72 hours after the administration of i.v. ketamine at a dose of 0.5 mg/kg for 40 min [16, 17]. In 2019, (S)-ketamine, under the name Esketamine, was approved by the FDA for the treatment of patients affected by Treatment-Resistant Depression (TRD) [18]; the repurposing of ketamine in depression therapy and related disorders can henceforth become a concrete alternative to StAD and may soon enable clinicians to define the ideal patient who can benefit mostly from ketamine or esketamine therapy [19, 20].

1.4 Mechanism of Action of Antidepressants

Understanding the mechanism of action of ketamine in the treatment of depression is undoubtedly complicated by the difficulty of comparing its mechanism of action with that of StAD. Indeed, ketamine differs from these drugs in its capacity to block the N-methyl-D-aspartate (NMDA) receptor and in its capability of manifesting a rapid antidepressant effect [15, 21]. Nonetheless, serotonin [22] and norepinephrine transmission [23, 24], which are the target of StAD, could be involved in producing the antidepressant effects of ketamine. By contrast, therapy with StAD is known to be based on blocking either the serotonin or the noradrenaline reuptake or both [25], while the dopamine reuptake, with the exception of bupropion, is not a target of these drugs. Long term therapy with antidepressants results in the enhancement of serotonergic and noradrenergic transmission through a complex mechanism that involves changes in adrenergic and serotonergic receptor density or sensitivity, changes in receptor G-protein coupling and cyclic nucleotide signalling. This therapy can also determine induction of neurotrophic factors, as well as increasing neurogenesis in the hippocampus [26].

Interestingly, although the dopamine reuptake system does not appear to be directly involved in the effects of StAD, norepinephrine reuptake blockers may increase dopamine synaptic concentrations in areas implicated in depression, such as the medial Prefrontal Cortex (mPFC) the Nucleus Accumbens (NAc) and the BNST. This is likely to be the case because dopamine is recaptured by the norepinephrine transporter [27]. Consequently, in the light of the important role that dopamine transmission has acquired in the treatment of depression, with regard specifically to anhedonia and motivated behaviour [28, 29], it does appear surprising that dopaminergic drugs do not play a relevant role in the therapy of depression [30, 31]. On the other hand, dopamine involvement in the antidepressant effects of ketamine is to be considered highly likely [32].

1.5 Aim

This review aims to examine which of the brain circuits that are involved in depression play a crucial role in the antidepressant mechanism of ketamine action and which circuits are also involved in the effects of StAD.

In order to better explain the role of specific brain areas in the mechanism of action of ketamine, it will be initially necessary to evaluate the pharmacological action of ketamine on those parameters, such as BDNF expression and release, or hippocampal neurogenesis, which are objectively altered in the specific brain areas of depressed patients as well as in AnMD [33]. Considering that chronic stress has been used as a powerful tool in reproducing rodent models of depression, and that chronic stress generates biochemical changes and receptor adjustments at the neuronal level in specific brain regions, we will also discuss the capacity of ketamine and StAD to reverse these changes in order to better clarify their mechanism of action. This evaluation will enable us to highlight some specific brain circuits that are involved in ketamine effects but could also play a pivotal role in understanding the therapeutic action of new potential antidepressant agents and in the aetiology of depression itself.

2. The Mechanism of Action of Ketamine and Pharmacokinetic Considerations Involved in its Rapid and Sustained Antidepressant Effect
2.1 Mechanism of Action

Ketamine is a non-competitive antagonist for the NMDA-type glutamate receptor site [34, 35, 36]. Ketamine binds to the phencyclidine site within the channel in the open ionic state, preventing the flux of sodium and calcium ions [37]. The involvement of NMDA-type glutamatergic transmission in depression is suggested by its adaptive response observed following treatment with antidepressants [38, 39]; although the antidepressant action of ketamine was initially reported as early as 2000 [10], the role of glutamatergic transmission in depression and in ketamine’s mechanism of action is far from being fully clarified [40, 41] (Fig. 1). One reason why there is an obstacle to understanding this role is undoubtedly because of the extensive distribution of glutamatergic transmission in the mammalian brain, and the different role of NMDA receptors in healthy versus diseased brains [42, 43, 44, 45] (Fig. 1).

Fig. 1.

Schematic representation of several major glutamatergic input pathways on mammalian brain nuclei where ketamine might interact with glutamate transmission by acting on NMDA and/or AMPA receptors to produce the antidepressant effects. Abbreviations: PFC, prefrontal cortex; Hipp, hippocampus; NAc, nucleus accumbens; LHb, lateral habenula; Amy, amygdala; VTA, ventral tegmental area; BNST, bed nucleus of stria terminalis. Glutamate (Glu), dopamine (DA) and GABA neurons and axons are represented.

Consequently, even though the antidepressant effects of ketamine were initially observed (as early as 1999) to overlap with those of imipramine in AnMD [46] and the antidepressant effects of ketamine have since been extensively reproduced using the raceme (R,S)-ketamine, at a dose of 10 mg/kg [47], a full understanding of the mechanisms underlying the rapid antidepressant action of ketamine has remained limited. Furthermore, if we were to accept that ketamine acts as an antagonist of NMDA glutamate transmission, how can we reconcile this observation with the fact that chronic stress reduces glutamate transmission in both the hippocampus [48, 49] and prefrontal cortex [50]? Indeed, ketamine is known to be able to curb the typical changes brought about by chronic stress-induced depression [41, 49]. To provide an answer to this question, it has been suggested that ketamine may act through the reduction of glutamatergic stimulatory transmission on a GABAergic inhibitory interneuron, which under physiological conditions inhibits a cortical pyramidal or hippocampal glutamatergic neuron [37, 51]. This explanation may corroborate the evidence that chronic stress in general reduces glutamate transmission and is in agreement with the observation that ketamine restores it in animal models of depression [49].

2.2 Ketamine Enantiomers and Metabolism

A second obstacle to understanding ketamine’s mechanism of action is the possibility that both the S and R enantiomers and their related metabolites are involved in its therapeutic effect [52]. Indeed, it is interesting to note that the S-enantiomer of ketamine has a fourfold higher affinity for NMDA receptors (Ki 0.7 μM) than R-ketamine (Ki 2.6 μM) [53], and that no significant psychotic symptoms are observed after injection of the same dose of R-ketamine [54]. In addition, several studies have suggested that (R)-ketamine is in fact a safer antidepressant than (R,S)- or (S)-ketamine [55]. Moreover, the metabolite (2R,6R)-Hydroxynorketamine [(2R,6R)-HNK)] can produce antidepressant effects that are observable in behavioural models in mice, most likely through activation of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, independently of the NMDA receptor. This would suggest that the antidepressant effects of ketamine do not require the generation of dissociative effects for them to manifest [52, 56].

A more in-depth discussion of the role of metabolites in the rapid and sustained antidepressant action of ketamine is not among the objectives of this review and can be examined in previous publications [19, 37, 57]. The above observations essentially suggest that the antidepressant effects of ketamine may manifest either through its antagonist action on the NMDA receptor or through potentiation of glutamate transmission through AMPA receptors. In addition, although these features enable us to explain how ketamine modifies the glutamate transmission in the hippocampus and in the mPFC, what remains to be clarified is the role of ketamine in the other brain areas that are involved in depression such as the NAc, the BNST, the amygdala and the LHb and how these areas interact with the mPFC and the hippocampus. Another important aspect of ketamine’s mechanism of action is its ability to induce a rapid and long-lasting antidepressant effect. It should be noted though, that this effect can last up to one week, during which time the plasma concentration of ketamine becomes irrelevant [15].

2.3 Pharmacokinetic Considerations

Although an in-depth pharmacokinetic and pharmacodynamic discussion of ketamine’s action is not among the objectives of this review, we feel it will be useful to clarify a few details as we refer to some recent publications for an argued evaluation [19, 58]. A first intriguing point serves to comprehend what the mechanism that activates the antidepressant response of ketamine may be; in particular, when evaluating the response to a single infusion of 0.5 mg/kg of (R,S)-ketamine, one observes the very rapid appearance of dissociative and psychotomimetic effects, which then gradually disappear in 60–120 min [59]. Nevertheless, given that this appearance is clearly generated by the achievement of an effective plasma concentration, it is hard to associate it with the activation of neuronal circuits, which allow the therapeutic antidepressant effect to take effect. Furthermore, there is a temporal correlation between the onset of behavioural effects, the occupation of NMDA receptors and the plasma or cerebral concentration of ketamine in different animal species [58]. A recent meta-analysis compared the efficacy of racemic ketamine with that of esketamine in bipolar and MDD subjects, concluding that intravenous ketamine appears to be more efficacious than intranasal esketamine [60]. In conclusion, ketamine and esketamine represent an innovative pharmacological opportunity for TRD, although concerns do remain about safety and tolerability of repeated and long-term treatment [20, 61].

3. Ketamine and BDNF Signalling in Brain Areas

To shed light on the role that brain circuits play in depression and in the mechanism of action of ketamine, we will look at BDNF expression and release in specific brain areas. BDNF is a 118 amino acid peptide and possesses wide neurotrophic effects implicated in neurogenesis, neuronal survival and differentiation, synaptic plasticity and Long-Term Potentiation (LTP) [62]. An altered function of BDNF has been implicated in the emergence of several neurological and psychiatric syndromes such as mood and anxiety disorders [63, 64] (Fig. 2).

Fig. 2.

Schematic representation of BDNF changes in several brain areas of animal model of depression (up arrow, BDNF increase; down arrow, BDNF decrease). Abbreviations: PFC, prefrontal cortex; Hipp, hippocampus; NAc, nucleus accumbens; LHb, lateral habenula; Amy, amygdala; VTA, ventral tegmental area; BNST, bed nucleus of stria terminalis.

BDNF can be released from presynaptic terminals or from dendrites, and act on TrkB (Tropomyosin receptor kinase B) receptors to activate cell growth and differentiation [65]. In particular, by instigating neuronal circuitry rewiring [9] BDNF is involved in the therapeutic action of StAD and ketamine. Depending on the brain area considered, ketamine will determine different BDNF responses. We will now examine its effects in the hippocampus, mPFC, NAc, amygdala, LHb and BNST.

3.1 Hippocampus
3.1.1 Hippocampus, BDNF and Depression

BDNF has a unique role in the hippocampus, where it is involved in learning and LTP [66]. It is widely recognised that expression of the BDNF is reduced in the hippocampus of depressed patients and in the hippocampus of AnMD [33, 67], although the cause-effect relationship of this observation is not clear. Furthermore, chronic stress is known to cause a down-regulation of BDNF protein and mRNA in the hippocampus [68], an effect that is closely linked to depression [53]. Conversely, while treatment with StAD increased the expression of BDNF mRNA in the hippocampus [69, 70, 71], repeated electroconvulsive seizure treatment can also increase expression of the BDNF protein in the hippocampus [72].

3.1.2 Effect of Ketamine on BDNF in Hippocampus

The effect of ketamine on the hippocampus is also closely linked to that of the BDNF; indeed, the presynaptic modulation of vesicular glutamate release [73] and the postsynaptic modulation of glutamate receptor trafficking can be attributed to BDNF, as demonstrated by the increase of AMPA receptors in hippocampal slices and neuronal culture [74]. Bearing in mind that in the hippocampus, as well as in the mPFC, ketamine activates the cellular and molecular mechanisms that underlie synaptic strengthening and dendritic spine formation, it is quite likely that BDNF mediates these effects, and that ketamine can generate them through the release of BDNF [49, 51]. Direct evidence of this effect is provided by Autry et al. [75], who observed that ketamine (3 mg/kg i.p.) increased BDNF protein expression in the hippocampus after only 30 minutes’ treatment. Recently, it has been suggested that ketamine can increase BDNF release in the hippocampus through the blockade of postsynaptic NMDA receptors [37] followed by synthesis of eukaryotic Elongation Factor2 (eEF2), similar to that proposed by Autry et al. [75]. Moreover, these authors provided evidence for an increase of TrkB phosphorylation, an indicator of TrkB activation in the hippocampus, suggesting that BDNF-TrkB signalling in the hippocampus is involved in the antidepressant response to ketamine [74]. Complementary to this observation is the finding that a loss of hippocampal BDNF per se is not sufficient to mediate depression-like behaviour, but BDNF in the dentate girus might be essential in mediating the therapeutic effects of antidepressants [76].

3.1.3 Hippocampal Volume and Neurogenesis

Together with BDNF, hippocampal volume and hippocampal neurogenesis are parameters that can be assessed to test the response of ketamine or StAD in AnMD or in patients affected by MDD. Indeed, the volume of the hippocampus is reduced in MDD patients [77, 78] and although a few studies have reported contrasting results [79], most have confirmed this observation. Interestingly, the antidepressant effects of ketamine were observed in patients who have a relatively smaller hippocampus and were refractory to StAD [80]. Another crucial issue in the aetiology of depression is the hippocampal neurogenesis, a process by which 700 new-born hippocampal granule cells are normally added daily in adult humans [81]. This process should allow the distinguishing and storing of similar experiences as distinct memories; the weakening of this process is of relevance as a biomarker of MDD, although some limits should be considered [82]. Neuroimaging and post-mortem studies in MDD patients have shown that neuronal atrophy is likely to be associated with a reduction of neurogenesis [83, 84, 85, 86]. Similar to the effects on hippocampal BDNF, chronic stress decreases hippocampal neurogenesis, while StAD can reverse this decrease [87, 88, 89]. It is known that neurogenesis can be stimulated either by therapy with StAD, or by physical exercise by activating not only progenitors but also stem cells, which are normally not stimulated [90]. Interestingly, the delay in the onset of the StAD effect after chronic administration has often been attributed to the time needed for new neurons to be recruited into memory circuits.

3.1.4 Effect of Ketamine on Hippocampal Neurogenesis

Given this, it is even more challenging to try and understand how ketamine produces its rapid and long-lasting antidepressant effects. Deyama and Duman [51], who recently reviewed this issue, have suggested that neurogenesis is involved in the sustained but not in the fast actions of ketamine. Although it reconciles the effects of ketamine with those of StAD, this hypothesis raises a doubt about the indispensability of the reactivation of hippocampal neurogenesis for the therapeutic manifestation of the rapid effects of antidepressants. On the other hand, a further testimony to the crucial role of hippocampal neurogenesis has been provided by Yamada and Jinno [91], who reported that, just two days after the administration of a single dose (10 mg/kg i.p.), ketamine elevated the density of neuronal progenitors and new-born granule cells in the ventral but not in the dorsal hippocampus in adult mice. Notably, the densities of neuronal stem cells were not affected by ketamine in either area. The preferential action of ketamine on ventral hippocampus (vHipp) neurogenesis is consistent with the role of this area in emotional processes and memories, while the dorsal part is related to spatial memory [92]. These results not only confirm neurogenesis to be a complex phenomenon but also suggest that new therapeutic tools, to be used as a complementary therapy of StAD, could generate a partial and temporary reactivation of neurogenesis.

3.1.5 Antidepressant Effects of Ketamine and Hippocampus

Furthermore, it has been suggested that ketamine activation of hippocampal neural activity may bring about protective action against stress-induced depressive-like behaviour, as suggested by the results of Mastrodonato et al. [93]. They showed that a single injection of ketamine (30 mg/kg, one week before), selectively increased DeltaFosB expression in the vHipp though only in mice exposed to social defeat stress [93]. Interestingly, the inactivation of the vHipp with lidocaine was able to prevent the sustained but not the acute antidepressant effect of ketamine, evaluated by forced swim test in Sprague-Dawley rats [94]. The authors therefore suggested that the activity in the vHipp-mPFC pathway is both necessary and sufficient for the antidepressant-like effect of ketamine to take place [94]. In short, we are suggesting that the antidepressant action of ketamine may occur as a result of a direct effect on the hippocampus, as supported by its effect on BDNF release and neurogenesis, although the connections that the hippocampus establishes with the mPFC and the NAc/Ventral Tegmental Area (VTA) suggest that it would be more appropriate to consider the global interaction of ketamine with a hypothetical primary circuit of depression (Fig. 3). This is also in consideration of the role of the mPFC in the cognitive aspects of depression, that of NAc/VTA in motivational behaviour and that of the hippocampus in its ability to control emotional memories.

Fig. 3.

Schematic representation of interactions among the brain areas that are involved in the “primary circuit of depression”, according with our hypothesis. Abbreviations: PFC, prefrontal cortex; Hipp, hippocampus; NAc, nucleus accumbens; VTA, ventral tegmental area.

3.2 Prefrontal Cortex
3.2.1 PFC Volume, BDNF and Depression.

Among the brain areas affected by depression, the mPFC has been widely investigated and many stimulating hypotheses about its role in depression have been advanced on the basis of several objective observations [95]. Among these, it is of some relevance that post-mortem studies have reported a reduced volume of several mPFC subregions in patients suffering from MDD and/or exhibiting suicidal thoughts and behaviours [96]. In particular, a reduction in size and density of neurons of dorsolateral mPFC has been observed [97, 98]. In addition, a decrease in synapse-related genes has been observed in AnMD [99]. An interesting report by Deyama and Kaneda [100] showed that a single injection of BDNF into the mPFC of mice produced long-lasting (8 days) antidepressant effects, in some way similar to the rapid and sustained antidepressant effect produced by ketamine [69]. Moreover, in the mPFC of subjects with MDD, the expression level of BDNF transcript variants and synaptic markers are selectively reduced [101].

3.2.2 Effect of Ketamine on BDNF in the mPFC

Several studies have shown that the increased release of BDNF in mPFC may be the means by which ketamine produces its antidepressant effects. Indeed, preclinical studies have shown that both (S)-ketamine (10 or 50 mg/kg i.p.) and the ketamine metabolite (2S,6S)-HNK (10 mg/kg i.p.) stimulate BDNF release in the mPFC of mice [102, 103]. Furthermore, it was observed that the antidepressant effects of ketamine (10 mg/kg i.p.) can be blocked by the administration of an antibody against BDNF in the mPFC of rats [104]. Additionally, a direct effect of ketamine (0.5 μM) on BDNF release was observed in a primary culture of cortical neurons, and, interestingly, this release can be blocked by NBQX, an AMPA receptor antagonist, or by Verapamil, an antagonist of L-type calcium channels [104]. It has been suggested that ketamine increases BDNF release through inhibition of the eEF2, resulting in reduced phosphorylation of eEF2 [104].

3.2.3 Mechanism of Action of Ketamine in the mPFC

It is apparently incongruent that ketamine activates BDNF release because it reduces rather than stimulates glutamate transmission. One explanation for this apparent incongruity holds that NMDA receptor blocking activity occurs pre-synaptically on the terminals of GABA interneurons in the medial mPFC and thereby reduces the inhibitory activity of these neurons. Thus, the reduction of GABA inhibitory activity would allow an increased release of glutamate, which through NMDA receptors would in turn activate BDNF release; this is followed by rapid exposure of AMPA receptors located on pyramidal neurons projecting towards subcortical areas, or on other pyramidal cells [19, 37, 51, 105, 106]. Activation of AMPA receptors allows calcium entry via voltage-dependent calcium channels and the subsequent release of both BDNF and the vascular endothelial growth factor. These two factors induce transduction and synthesis of further factors that mediate activation of synaptogenesis and dendritic spine maturation, including GluA1 and postsynaptic density protein 95 through the TrkB/Flk-1—mammalian Target of Rapamycin (mTOR) complex1 signalling pathway [107]. Likewise, these investigators suggested that direct activation of postsynaptic AMPA receptors, resulting in increased extracellular glutamate and GABA levels in the mPFC, is involved in the antidepressant effects of the ketamine metabolite HNK [37].

3.2.4 Effect of Ketamine on Neuronal Plasticity in the mPFC

The rapid effects of ketamine on neuronal plasticity in the mPFC has been observed in rodents [108]; these authors have shown that a single administration of a low dose of ketamine promptly activated the mTOR signalling, resulting in a long-lasting increase of spine and synapse-associated proteins in the rat mPFC. Notably, repeated stress induces an opposite effect, with dendritic spine loss in the rat mPFC [109]. Furthermore, Moda-Sava et al. [110], demonstrated that ketamine reversed the loss of postsynaptic dendritic spines induced by chronic stress or chronic corticosterone in a mouse model of depression. These authors also demonstrated that specific elimination of postsynaptic dendritic spines on mPFC projection neurons was temporarily associated with the manifestation of depressive behaviour and that antidepressant doses of ketamine, in addition to counteracting behavioural manifestations, resulted in regeneration of the spines; they further suggested that synaptogenesis might be a means by which the long-lasting antidepressant effects (but not the rapid ones) of ketamine are manifested [110]. This last hypothesis is not in agreement with the increased level of synaptic proteins (i.e., PSD-95, synapsin-1, and GluA1) that Li et al. [108] observed as early as 2 h after ketamine administration. Therefore, it can be attested that a local activity-dependent synaptogenesis in the mPFC pyramidal neurons is an essential feature of the antidepressant effects of ketamine [51].

3.3 Nucleus Accumbens
3.3.1 NAc Inputs and Outputs

The NAc receives excitatory glutamatergic innervation from different brain areas involved in depression such as the hippocampus, mPFC, basolateral amygdala and thalamus [111, 112, 113, 114] (Fig. 1), supporting the hypothesis of its key role in modulating individual susceptibility to depression and thus its potential to be a target area for the antidepressant actions of ketamine. The VTA provides the dopaminergic input to the NAc [115] but also to many other brain areas involved in depression such as the mPFC, hippocampus, BLA and BNST [116]. VTA neurons are in turn innervated by GABA projection from NAc and BNST, whereas glutamate neurons originating in the mPFC, LHb and amygdala also innervate VTA [19] (Figs. 1,4).

Fig. 4.

Schematic representation of glutamate (Glu), GABA and dopamine (DA) inputs and outputs among the brain areas involved in the “primary circuit of depression”. Abbreviations: PFC, prefrontal cortex; Hipp, hippocampus; NAc, nucleus accumbens; VTA, ventral tegmental area.

Interestingly, inputs from the hippocampus and mPFC converge on the same NAc neuron, a feature that would suggest the existence of a hippocampal gating of other limbic inputs [117] and in particular that vHipp afferents to NAc regulate susceptibility to depression [118]. The NAc is a central component of the ventral striatum and integrates limbic and cortical signals to modulate goal-directed behaviour through the modulatory action of dopamine [119]. For its role in the reward circuit, in motivated behaviour, in hedonic appraisal, mood regulation and in anhedonia in general (decreased drive for activities because of the reduced capacity to feel pleasure and satisfaction for the associated outcomes), NAc has been implicated in the aetiology of depression [28, 120].

3.3.2 BDNF in NAc and Depressive Like Behaviours

NAc mesolimbic pathway and the BDNF expression, has a fundamental role in mediating the effects of social defeat stress and those of antidepressants; in particular, after local deletion of BDNF in the VTA, the effects of social defeat stress on gene activation in the NAc was lost or reversed, as was the effect of chronic fluoxetine [121]. BDNF signalling is highly represented in the VTA-NAc circuit; in particular, one major source of BDNF in both regions is provided by a glutamatergic afferent from mPFC, hippocampus and amygdala, while release of BDNF is recognised by TrkB receptors expressed on VTA dopaminergic and NAc GABAergic neurons [28]. In general, the changes in BDNF release induced by chronic stress in the NAc further support its pivotal role in the generation of depression [28]. Additionally, the phasic stimulation of VTA neurons that project to NAc, but not those that project to the mPFC, induced susceptibility to social defeat stress in mice [122]. In particular, stress increases the release of BDNF in the NAc, an effect that was mediated by Corticotrophin Releasing Factor (CRF) [123]. It was subsequently suggested that BDNF–TrkB signalling but not dopamine signalling in the VTA-NAc circuit, was an essential component in the development of depressive-like behaviours induced by chronic stress [124]. Interestingly, it has also been shown that a BDNF increase (namely 90% elevation) in the NAc occurs only in susceptible mice [125]. Direct evidence of the NAc-BDNF role in promoting depression-like behaviour has been provided by the observation that direct infusion of BDNF into the NAc increases the immobility in forced swim tests (FST), while inhibition of TrkB signalling in the NAc decreases immobility [126].

3.3.3 Ketamine Effect on NAc Dopamine Transmission

Looking at the role of NAc in mediating the antidepressant effect of ketamine, it is of interest that ketamine and LY341495 (a potent and selective antagonist of group II metabotropic glutamate receptor [127]), but not the selective serotonin reuptake inhibitor (SSRI) citalopram, increased the number of spontaneously active dopamine neurons in the VTA, and the extracellular dopamine levels in the NAc as well as in the mPFC [128], an effect that was shown to be AMPA-dependent. Although the abuse potential of ketamine [129] would suggest there may be direct ketamine action on dopamine transmission through an interaction with dopamine reuptake, or with dopamine receptors, it has been demonstrated that such an occurrence is unlikely [130].

3.3.4 Ketamine Effect on LTP and LTD

Stress is known to affect synaptic plasticity by inhibiting LTP and/or facilitating long term depression (LTD) in the hippocampus of rodents [131] and we also know that ketamine and its metabolite (2R,6R)-HNK restore LTP and long-term memory in the Wistar-Kioto rat model of depression that likely own an alteration of dopamine stores [132, 133]. As regards NAc, ketamine restores normal neuron population activity and restores LTP in the ventral subiculum-NAc pathway, thus suggesting that normal LTP in the NAc shell prevents the generation of helplessness [134]. On the other hand, a single low dose injection of ketamine (3–5 mg/kg) dose-dependently induced the impairing of LTP in the NAc at 24 h after administration; this effect was maintained for 7 days and was not associated with any alteration of basal synaptic transmission mediated by AMPA and NMDA receptors [135]. Similar results were previously shown by Réus et al. [136], who reported that both ketamine and imipramine impaired histone deacetylation in the NAc; this function was found to increase in the NAc but not in the mPFC, hippocampus, and amygdala in maternally deprived adult Wistar rats. This may well be relevant with regard to long-term changes related to stress and antidepressant treatment.

3.3.5 Ketamine Effect on NAc Volume

Further evidence of NAc involvement in ketamine’s effects was obtained by Abdallah et al. [137] in a MDD subgroup of patients displaying an enlarged bilateral NAc volume; these authors observed that ketamine treatment normalized NAc volume in patients who achieved remission. On the whole, the role of NAc in the appearance of peculiar symptoms of depression and in the antidepressant effects of ketamine supports its pivotal role in a primary circuit of depression; interestingly, the effects of stress, as well as the response to antidepressants (i.e., StAD and ketamine) on BDNF related actions in the VTA-NAc circuit appear to be opposite to those observed in the mPFC and hippocampus (Fig. 2).

3.4 Lateral Habenula
3.4.1 Connections and Functions of LHb and Dopamine Mediated Reward

The Lateral Habenula (LHb) has recently been implicated in the coding of negative emotions [138]. In particular, the functions of the LHb are associated with anxiety, stress, pain, avoidance learning, attention, human reward processing, psychosis and depression [139, 140, 141]. In consequence of the strong inhibition of dopamine neurons after a weak electrical stimulation of the LHb, it has been proposed that LHb provides a measure of control on VTA dopamine neurons, negatively influencing reward-related signals [138]. The capacity to reduce dopamine-mediated reward responsiveness validates the involvement of LHb in the occurrence of anhedonia, a typical feature in MDD patients [142] and possibly, in stress induced depression as reported by Shabel et al. [143]; these authors observed that acute stress can transform LHb reward responses into punishment-like neuronal signs. LHb is primarily a glutamatergic nucleus, and its output reaches the VTA and the dorsal raphe nuclei (DRN), where an inhibition of monoamine neurons can occur through the activation of GABAergic inhibitory neurons [144]. Glutamatergic LHb neurons are transiently activated by acute stress or aversive stimuli and likely mediate a wide range of responses, ranging from stress evasion to value-based decision-making [145]. The LHb receives projections from the mPFC, providing a link for conveying cognitive and affective information from prefrontal and insular regions to the midbrain monoaminergic centres [146] (Fig. 5).

Fig. 5.

Schematic representation of interactions among the lateral habenula (LHb) and the brain areas that are involved in the “primary circuit of depression”, according with our hypothesis. Some interactions of dorsal and median raphe with these brain areas are represented schematically. Other abbreviations: PFC, prefrontal cortex; Hipp, hippocampus; NAc, nucleus accumbens; VTA, ventral tegmental area; RN, raphe nuclei.

3.4.2 Ketamine Modulation of LHb Function

Based on this assumption, and considering the role of ketamine in the mPFC, it should not be surprising that ketamine may well produce its rapid antidepressant action through modulating the LHb function either directly or through the modulation of mPFC activity. Indeed, in a rat and mouse model of depression, in which burst-evoking photo-stimulation of the LHb can result in despair and anhedonia, it has been reported that because it blocks NMDA receptor-dependent burst firing in the LHb, ketamine can reduce stimulation of inhibitory neurons in the VTA, disinhibiting the NAc reward centre [142]. Similarly, ketamine can persistently (up to 72 h post injection) reverse maternal deprivation-induced intrinsic neuronal excitability in the LHb and decrease immobility in the forced swimming test in late adolescent male rats [147].

3.4.3 BDNF in the LHb and Depressive Like Behaviours

As far as the LHb BDNF role in AnMD is concerned, the few reports available have not enabled us to gain any clearer understanding of the mechanism involved. In addition, BDNF immunoreactivity in the habenula is mostly distributed in the medial part and is concentrated in fibers [148]. BDNF level expressions in the LHb were found to be higher than in controls of Chronic Restraint Stress (CRS) exposed mice, together with higher levels of GluN2B and c-Fos. Interestingly, the systemic administration of the specific GluN2B antagonist rislenemdaz, a drug used in phase II clinical trials as an antidepressant, reversed CRS effects while its infusion in the LHb decreased immobility time in CRS-exposed mice [149]. These authors have also showed that knocking down BDNF in the LHb prevented CRS-induced despair-like behaviour and inhibited neuronal activity in the LHb. Curiously, 6-hydroxydopamine lesions in the ventral region of the caudate putamen determined a reduction of BDNF and TRkB mRNA levels in the hippocampus, as well as in the BDNF mRNA in the habenula. By contrast, the lesions did not influence BDNF and TRkB expression in the NAc and in the VTA, whereas chronic imipramine reversed BDNF mRNA reduction in the dentate girus of the hippocampus [150].

3.4.4 Role of the LHb in Depression Associated Inflammation

A recent interesting study investigated the role of the LHb in depression-associated inflammation by using the Unpredictable Chronic Stress (UCS) animal model of depression [151]. These researchers observed an increase of inflammatory cytokines in the CNS, especially in the LHb; conversely, local administration of tumor necrosis factor-alpha in the LHb, can induce depressive-like behaviour in control rats. Lastly, they showed that lesioning LHb prevented the impairment of hippocampal neurogenesis and a reduction of the hippocampal function in UCS exposed rats [151].

Summing up, it appears that an inappropriate LHb firing activity could play a decisive role in the aetiology of depression, while its peculiar intrinsic activity and connections with the other brain areas involved in depression means that we can consider the LHb to be a further site through which the rapid action of ketamine occurs [152] (Figs. 5,6).

Fig. 6.

Schematic representation of glutamate (Glu) GABA, dopamine (DA) and serotonin inputs and outputs among the lateral habenula (LHb), and the brain areas involved in the “primary circuit of depression”. Some inputs and outputs of dorsal and median raphe with these brain areas are represented schematically. Other abbreviations: PFC, prefrontal cortex; Hipp, hippocampus; NAc, nucleus accumbens; VTA, ventral tegmental area; RN, raphe nuclei.

3.5 Amygdala
3.5.1 Amygdala Connections, BDNF and Stress

The amygdala is composed of a series of heterogeneous subnuclei that differ both morphologically and functionally. Notably, the basolateral amygdala (BLA) is primarily glutamatergic [153], whereas the central nucleus of amygdala (CeA), which includes the centrolateral and the centromedial nuclei, consists of 95% GABAergic medium spiny neurons [154]. The BLA projects to the mPFC, hippocampus and NAc [155] thus interacting directly with the primary circuit of depression. CRS triggers dendritic growth and spinogenesis in the neurons of the BLA, regardless of whether or not they project to the mPFC [150]. CRS leads to increases of BDNF mRNA and BDNF protein and dendritic spine density in the BLA, which are strikingly different from those seen in the hippocampus and in the mPFC [156, 157, 158, 159].

3.5.2 Amygdala Function and Depression

Structural alteration and decreased function in the mPFC and hippocampus, but an increased function and an altered morphology in the amygdala were observed in MDD patients during clinical and post-mortem studies [160, 161]. The decreased connectivity and function in the mPFC may well contribute to the appearance of cognitive symptoms of depression while any augmented function of the amygdala may alter emotions and mood, increase fear and anxiety and hyper-activate the hypothalamic-pituitary-adrenal axis [159]. In this regard, it is of interest to note the suggestion that prelimbic mPFC excites amygdala output, while infralimbic mPFC inhibits it, providing a mechanism of bidirectional modulation of fear expression [162]. In a fear-generalized mouse model, a single administration of ketamine (30 mg/kg i.p.) reversed the reduction of BDNF levels induced by fear generalization in the BLA and in the infralimbic mPFC [163].

3.5.3 Amygdala and Cellular Biochemical Changes

As for the evaluation of intracellular proteins (i.e., PSD-95) and NMDA glutamate receptor subunits (i.e., NR2A), it is worth noting that they are both increased in the amygdala of depressed humans, whereas they are decreased in the mPFC [164]. In addition, chronic variable stress reduces histone deacetylases-5 in the CeA of male rats [165], similar to that caused by chronic social defeat stress in mice [166]; by contrast, histone deacetylase does not seem to change in the mPFC after acute or chronic stress [167, 168]. In brief, it seems that the amygdala is definitely involved in the generation of depression, because of the biochemical and morphological changes induced by chronic stress, although there is scarce evidence of its involvement in the antidepressant effects of ketamine. Interestingly, many of the BDNF related or unrelated changes induced by chronic stress in the amygdala are opposite to those seen the hippocampus and in the mPFC.

3.6 Bed Nucleus of Stria Terminalis
3.6.1 BNST, Connections and Stress Response

The BNST is a complex limbic structure that plays a crucial role in the regulation of fear, anxiety and aversion [169, 170, 171], in the integration of stress response [172, 173, 174, 175] as well as in the acquisition of emotions and motivated behaviour [176] (Fig. 7). Consequently, since diminished motivation is an essential feature of depression [28], it is likely that it is extensively involved both in developing and sustaining depression as well as in the mechanism of action of StAD and ketamine [19, 24, 177]. The BNST’s role in anxiety and depression is also evidenced by a serotonergic innervation of the BNST [178, 179]; interestingly, the availability of serotonin reuptake sites in the BNST is positively correlated with individual differences in anxiety behaviour [180]. The BNST receives glutamatergic projections from the mPFC, from the hippocampus and the basomedial amygdale, whereas GABAergic inputs arise from central and medial amygdaloid nuclei [181] (Fig. 8). The noradrenergic innervation of the BNST arises from the A2 region of the nucleus of the solitary tract and the A1 region of the caudal brainstem, with a minor projection from the locus coeruleus [182, 183]. These inputs are involved in stress response [184] and in arousal [185]. In particular, the BNST may act as a node for signal integration and coordination for appropriate homeostatic physiological and behavioural responses, a function which is likely reinforced by more than a dozen neuropeptides co-expressed in BNST neurons [175]. Hence, the insufficient resilience capacity of the BNST in handling long-duration threats associated with chronic stress can be a crucial occurrence in the development of depression.

Fig. 7.

Schematic representation of interactions among the bed nucleus of stria terminalis (BNST) and the brain areas that are involved in the “primary circuit of depression” according with our hypothesis. Some interactions of dorsal and median raphe with these brain areas are represented schematically. Other abbreviations: PFC, prefrontal cortex; Hipp, hippocampus; NAc, nucleus accumbens; VTA, ventral tegmental area; RN, raphe nuclei.

Fig. 8.

Schematic representation of glutamate (Glu), GABA, dopamine (DA) and serotonin (5-HT) inputs and outputs among the bed nucleus of stria terminalis (BNST) and the brain areas involved in the “primary circuit of depression”. Some inputs and outputs of dorsal and median raphe with these brain areas are represented schematically. Other abbreviations: PFC, prefrontal cortex; Hipp, hippocampus; NAc, nucleus accumbens; VTA, ventral tegmental area; RN, raphe nuclei.

3.6.2 BNST and VTA Neurons

In addition, the BNST receives a dense dopaminergic innervation [186] that clearly involves the circuits that mediate reward appraisal [187, 188] and in stress-induced relapses of drug-seeking [189], thereby suggesting that drug addiction shares common neurocircuitry with depression. Part of this neurocircuitry is the BNST output to the VTA; in fact, it has been shown that GABAergic efferent from the BNST forms symmetrical synapses on VTA neurons, which are mostly GABAergic neurons [190]. The activation of this output, mediated by glutamate innervation in the BNST is likely to disinhibit VTA dopaminergic neurons; in addition, dopamine and norepinephrine projections on the BNST innervate CRF neurons that in turn innervate glutamatergic afferents on BNST projecting neurons to VTA neurons [190, 191]. Although it was previously reported that the electrical stimulation of BNST can produce both excitatory and inhibitory responses in VTA neurons in vivo [192], it was recently reported that inhibitory synaptic transmissions to BNST neurons projecting to VTA are enhanced in rats exposed to chronic stress [193].

3.6.3 Effects of Ketamine on Glutamatergic Transmission in the BNST

Significantly, the 16 unique and complex sub-regions of the BNST [194, 195], and the multiple inputs from many limbic regions, mostly glutamatergic (e.g., basomedial and central amygdala, hippocampus, mPFC) but also GABAergic (from central and medial amygdaloyd nucleus [181]) and its multiple outputs (e.g., VTA, lateral hypothalamus, central nucleus of the amygdala, periacqueductal grey, parabrachial nucleus) [196, 197], does not allow us to predict whether or not ketamine, through its direct interaction with the glutamatergic transmission in the BNST, provides a substantial contribution to the manifestation of its rapid and sustained antidepressant effects. On the other hand, from the direct interactions of BNST with brain areas involved in anhedonia or in depression symptoms in general, it might be presumed that the BNST plays a central role in depression aetiology, as well as in the mechanism of action of antidepressants. This hypothesis is supported by the observation (albeit in a pilot study only) that patients affected by TRD could benefit from deep brain stimulation of the BNST [198]. Unlike other brain areas involved in depression, there have been very few investigations concerning the assessment of the BDNF expression in the BNST. In particular, what has been observed is that early-life stress alters affective behaviours in adult mice through the activation of CRF-BDNF signalling in the oval bed nucleus, which indicates enhanced neuronal plasticity [199].

3.6.4 Effects of Ketamine and StAD on Monoamine Transmission in the BNST

We have previously observed that StAD [177] and ketamine [24] shared the ability to increase dopamine and noradrenaline extracellular concentration in the BNST; interestingly, the SSRIs citalopram or fluoxetine and the selective blockers of norepinephrine reuptake such as desipramine or reboxetine and ketamine (i.e., 10–40 mg/kg i.p.) similarly increased the output of norepinephrine and dopamine. These data have enabled us to hypothesize that a converging pathway of activation of catecholamine transmission in the BNST could well play a determining role in the effect of antidepressants, although it is hard to predict whether this effect is due to a local action or to the involvement of a complex and integrated circuit of depression.

4. Discussion and Future Directions
4.1 Understanding the Aetiology of Depression

This review has discussed the role of several brain areas, namely the mPFC, hippocampus, NAc, VTA, amygdala, LHb and the BNST, in the behavioural expression of AnMD or in the occurrence of depression in humans and in the antidepressant effects of ketamine. In particular, the evaluation of the effect of ketamine in reversing the changes in BDNF expression and release, induced by chronic stress, gives further credence to the role of BDNF in depression and in ketamine’s antidepressant effects [33, 49, 200]. A considerable amount of data has been accumulated in investigating either monoamine transmission’s role in depression [201], together with biochemical markers, transmitters and receptors in specific brain areas of stressed rodents used as AnMD [202, 203]; the limited contribution of brain images of depressed patients [204, 205], or post-mortem brain analysis of brains of suicidal subjects [83, 84, 85, 86, 206], has not really contributed to further our understanding of the aetiology of depression [207]. However, it has been frequently reported that the alteration of one specific parameter in one specific brain area is sufficient to trigger depression-linked behavioural changes [69, 76, 94, 100, 142]. Are the various existing rodent models of depression too limited to represent such a complex disorder? Or is depression simply a pathological alteration that cannot be triggered by an alteration of one single brain area or one single biochemical parameter?

Approval for the clinical use of esketamine, and the broad experimental data on ketamine’s effects and mechanism of action in AnMD has made it viable to identify glutamatergic transmission as being a key element in depression; it has also given research a further step forward in understanding the aetiology of depression. Notably, the specific change of BDNF levels observed in different brain areas of AnMD [63, 64] suggests that the response of the brain to stress challenges is a loss of connectivity, synaptic density and strength in specific brain areas such as the hippocampus and the mPFC, while in others such as the amygdale, the NAc and possibly the BNST, the increase in BDNF levels would suggest the activation and strengthening of unhealthy circuitry.

4.2 Single Area Changes versus Circuitry Modification in Depression

Several reports suggest that alterations and their reversal in just one of these areas could be sufficient to trigger and reverse the onset of depression. However, if we consider the strict interconnections between and among these areas and the role of glutamate in these connections, it can be assumed that a continuous flow of communication among these brain areas is necessary and sufficient for the functioning of a healthy brain. The manifestation of depression symptoms, on the other hand, can be viewed as the result of a failure of brain circuits to handle new environmental challenges. We can thus identify the mPFC, the hippocampus and the NAc/VTA as being essential components of a brain circuitry that plays a pivotal role in the expression of depression and in turn in the therapeutic effects of antidepressants; we might call it the “primary circuit of depression”. Also noteworthy is the fact that ketamine rapidly increases the BDNF and VEGF in the mPFC as well as in the hippocampus; in the latter area ketamine also increases neurogenesis [57]; Indeed, hippocampal neurogenesis is also increased by StAD through adrenergic or serotoninergic pathways, specifically involving the cAMP-PKA-CREB-BDNF pathway [208], thus providing further proof of the pivotal role of the hippocampus in depression, even though the precise role of hippocampal neurogenesis in healthy humans has not yet been comprehensively clarified [81, 209]. We have previously described the critical importance of changes that occur in other brain areas involved in depression, such as the amygdala, the LHb and the BNST (including its close connection with the paraventricular nucleus of the hypothalamus); therefore, we believe that their connections with the stations of the primary circuit of depression are of fundamental importance in mediating the flow of inputs generated by stressful environmental changes. We also believe that a healthy circuit of depression can handle these challenges whereas an inadequate resilience of this circuit can trigger the appearance of depression symptoms. Unfortunately, the limited data on the effect of ketamine on BDNF expression and release in the amygdala, the LHb and in the BNST has not enabled us to properly evaluate their role in depression and in the therapeutic action of ketamine.

4.3 Conclusions and Future Directions

To sum up, we believe that further investigations on the potential role of ketamine in reversing the molecular and circuit alteration induced by chronic stress or other biochemical challenges in specific brain area of AnMD will provide further insights required to explain the workings of brain circuits involved in the behavioural expression of AnMD. Additionally, the clinical data that will be gained thanks to the FDA approval of esketamine to be used in the treatment of depression, will soon make it possible to ascertain whether or not ketamine can indeed be a cure for depression, at least in a significant number of patients. At the same time, approval will make it easier to characterize the potential risk of its abuse.

Abbreviations

AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AnMD, Animal Models of Depression; BDNF, Brain Derived Neurotrophic Factor; BNST, Bed Nucleus of Stria Terminalis; CRF, Corticotrophin Releasing Factor; CRS, Chronic Restraint Stress); eEF2, eukaryotic Elongation Factor2; HNK, Hydroxynorketamine; LHb, Lateral Habenula; LTP, Long Term Potentiation; MDD, Major depressive disorder; mTOR, mammalian Target of Rapamycin; NAc, Nucleus Accumbens; NMDA, N-methyl-D-aspartate; mPFC, medial Prefrontal Cortex; StAD, Standard Antidepressant Drugs; TRD, Treatment-Resistant Depression; vHipp, ventral Hippocampus; VTA, Ventral Tegmental Area.

Author Contributions

EC conceptualized, wrote and revised the full manuscript. AC contributed substantially to the revision of the full manuscript.

Ethics Approval and Consent to Participate

Not applicable.

Acknowledgment

The authors acknowledge the invaluable artwork of Archt. Elisabetta Carboni, for the preparation of the figures.

Funding

This research received no external funding.

Conflict of Interest

The authors declare no conflict of interest.

Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
[1]
Lopizzo N, Bocchio Chiavetto L, Cattane N, Plazzotta G, Tarazi FI, Pariante CM, et al. Gene-environment interaction in major depression: focus on experience-dependent biological systems. Frontiers in Psychiatry. 2015; 6: 68.
[2]
Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World Psychiatry. 2013; 12: 92–98.
[3]
Czéh B, Fuchs E, Wiborg O, Simon M. Animal models of major depression and their clinical implications. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2016; 64: 293–310.
[4]
Belzung C, Lemoine M. Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biology of Mood and Anxiety Disorders. 2011; 1: 9.
[5]
Robinson ESJ. Improving the Translational Validity of Methods used to Study Depression in Animals. Psychopathology Review. 2016; 3: 41–63.
[6]
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018; 391: 1357–1366.
[7]
De Carlo V, Calati R, Serretti A. Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: a systematic review. Psychiatry Research. 2016; 240: 421–430.
[8]
Wang Q, Timberlake MA, Prall K, Dwivedi Y. The recent progress in animal models of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2017; 77: 99–109.
[9]
Aleksandrova LR, Phillips AG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends in Pharmacological Sciences. 2021; 42: 929–942.
[10]
Hess EM, Riggs LM, Michaelides M, Gould TD. Mechanisms of ketamine and its metabolites as antidepressants. Biochemical Pharmacology. 2022; 197: 114892.
[11]
Barrett W, Buxhoeveden M, Dhillon S. Ketamine: a versatile tool for anesthesia and analgesia. Current Opinion in Anaesthesiology. 2020; 33: 633–638.
[12]
Nowacka A, Borczyk M. Ketamine applications beyond anesthesia – a literature review. European Journal of Pharmacology. 2019; 860: 172547.
[13]
Bates MLS, Trujillo KA. Use and abuse of dissociative and psychedelic drugs in adolescence. Pharmacology Biochemistry and Behavior. 2021; 203: 173129.
[14]
Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. Nature Reviews Drug Discovery. 2017; 16: 472–486.
[15]
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry. 2000; 47: 351–354.
[16]
aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. Canadian Medical Association Journal. 2009; 180: 305–313.
[17]
Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: a Two-Site Randomized Controlled Trial. American Journal of Psychiatry. 2013; 170: 1134–1142.
[18]
Turner EH. Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. The Lancet Psychiatry. 2019; 6: 977–979.
[19]
Carboni E, Carta AR, Carboni E, Novelli A. Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success? Frontiers in Neuroscience. 2021; 15: 657714.
[20]
Lengvenyte A, Strumila R, Olié E, Courtet P. Ketamine and esketamine for crisis management in patients with depression: why, whom, and how? European Neuropsychopharmacology. 2022; 57: 88–104.
[21]
Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression. Archives of General Psychiatry. 2006; 63: 856–864.
[22]
Sial OK, Parise EM, Parise LF, Gnecco T, Bolaños-Guzmán CA. Ketamine: the final frontier or another depressing end? Behavioural Brain Research. 2020; 383: 112508.
[23]
López-Gil X, Jiménez-Sánchez L, Campa L, Castro E, Frago C, Adell A. Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine. ACS Chemical Neuroscience. 2019; 10: 3318–3326.
[24]
Cadeddu R, Jadzic D, Carboni E. Ketamine modulates catecholamine transmission in the bed nucleus of stria terminalis: the possible role of this region in the antidepressant effects of ketamine. European Neuropsychopharmacology. 2016; 26: 1678–1682.
[25]
Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2013; 45: 54–63.
[26]
Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behavioural Pharmacology. 2007; 18: 391–418.
[27]
Carboni E, Silvagni A, Vacca C, Chiara G. Cumulative effect of norepinephrine and dopamine carrier blockade on extracellular dopamine increase in the nucleus accumbens shell, bed nucleus of stria terminalis and prefrontal cortex. Journal of Neurochemistry. 2006; 96: 473–481.
[28]
Nestler EJ, Carlezon WA. The Mesolimbic Dopamine Reward Circuit in Depression. Biological Psychiatry. 2006; 59: 1151–1159.
[29]
Coccurello R. Anhedonia in depression symptomatology: Appetite dysregulation and defective brain reward processing. Behavioural Brain Research. 2019; 372: 112041.
[30]
Hori H, Kunugi H. Dopamine agonist-responsive depression. Psychogeriatrics. 2013; 13: 189–195.
[31]
Tundo A, Filippis R, De Crescenzo F. Pramipexole in the treatment of unipolar and bipolar depression. a systematic review and meta‐analysis. Acta Psychiatrica Scandinavica. 2019; 140: 116–125.
[32]
Rincón-Cortés M, Grace AA. Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress. Behavioural Brain Research. 2020; 379: 112367.
[33]
Duman RS, Deyama S, Fogaça MV. Role of BDNF in the pathophysiology and treatment of depression: Activity‐dependent effects distinguish rapid‐acting antidepressants. European Journal of Neuroscience. 2021; 53: 126–139.
[34]
Martin D, Lodge D. Ketamine acts as a non-competitive N-methyl-d-aspartate antagonist on frog spinal cord in vitro. Neuropharmacology. 1985; 24: 999–1003.
[35]
Zorumski CF, Izumi Y, Mennerick S. Ketamine: NMDA Receptors and beyond. The Journal of Neuroscience. 2016; 36: 11158–11164.
[36]
Zhang Y, Ye F, Zhang T, Lv S, Zhou L, Du D, et al. Structural basis of ketamine action on human NMDA receptors. Nature. 2021; 596: 301–305.
[37]
Pham TH, Gardier AM. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. Pharmacology and Therapeutics. 2019; 199: 58–90.
[38]
Paul IA, Layer RT, Skolnick P, Nowak G. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. European Journal of Pharmacology. 1993; 247: 305–311.
[39]
Paul IA, Nowak G, Layer RT, Popik P, Skolnick P. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. The Journal of Pharmacology and Experimental Therapeutics. 1994; 269: 95–102.
[40]
Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GMI, et al. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology. 2018; 43: 2154–2160.
[41]
Duman RS, Sanacora G, Krystal JH. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 2019; 102: 75–90.
[42]
Adell A. Brain NMDA Receptors in Schizophrenia and Depression. Biomolecules. 2020; 10: 947.
[43]
Lalo U, Koh W, Lee CJ, Pankratov Y. The tripartite glutamatergic synapse. Neuropharmacology. 2021; 199: 108758.
[44]
Scheefhals N, MacGillavry HD. Functional organization of postsynaptic glutamate receptors. Molecular and Cellular Neuroscience. 2018; 91: 82–94.
[45]
Mkrtchian A, Evans JW, Kraus C, Yuan P, Kadriu B, Nugent AC, et al. Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. Molecular Psychiatry. 2021; 26: 3292–3301.
[46]
Chaturvedi HK, Chandra D, Bapna JS. Interaction between N-methyl-D-aspartate receptor antagonists and imipramine in shock-induced depression. Indian Journal of Experimental Biology. 1999; 37: 952–958.
[47]
Polis AJ, Fitzgerald PJ, Hale PJ, Watson BO. Rodent ketamine depression-related research: Finding patterns in a literature of variability. Behavioural Brain Research. 2019; 376: 112153.
[48]
Kallarackal AJ, Kvarta MD, Cammarata E, Jaberi L, Cai X, Bailey AM, et al. Chronic Stress Induces a Selective Decrease in AMPA Receptor-Mediated Synaptic Excitation at Hippocampal Temporoammonic-CA1 Synapses. Journal of Neuroscience. 2013; 33: 15669–15674.
[49]
Tornese P, Sala N, Bonini D, Bonifacino T, La Via L, Milanese M, et al. Chronic mild stress induces anhedonic behavior and changes in glutamate release, BDNF trafficking and dendrite morphology only in stress vulnerable rats. The rapid restorative action of ketamine. Neurobiology of Stress. 2019; 10: 100160.
[50]
Yuen E, Wei J, Liu W, Zhong P, Li X, Yan Z. Repeated Stress Causes Cognitive Impairment by Suppressing Glutamate Receptor Expression and Function in Prefrontal Cortex. Neuron. 2012; 73: 962–977.
[51]
Deyama S, Duman RS. Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine. Pharmacology Biochemistry and Behavior. 2020; 188: 172837.
[52]
Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016; 533: 481–486.
[53]
Hashimoto K. Rapid‐acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry and Clinical Neurosciences. 2019; 73: 613–627.
[54]
Vollenweider FX, Leenders KL, Øye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). European Neuropsychopharmacology. 1997; 7: 25–38.
[55]
Chang L, Zhang K, Pu Y, Qu Y, Wang S, Xiong Z, et al. Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacology Biochemistry and Behavior. 2019; 181: 53–59.
[56]
Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacological Reviews. 2018; 70: 621–660.
[57]
Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metabolism and Disposition. 2002; 30: 853–858.
[58]
Shaffer CL, Osgood SM, Smith DL, Liu J, Trapa PE. Enhancing ketamine translational pharmacology via receptor occupancy normalization. Neuropharmacology. 2014; 86: 174–180.
[59]
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry. 1994; 51: 199–214.
[60]
Bahji A, Vazquez GH, Zarate CA. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Journal of Affective Disorders. 2021; 278: 542–555.
[61]
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: an International Expert Opinion on the Available Evidence and Implementation. American Journal of Psychiatry. 2021; 178: 383–399.
[62]
Hall J, Thomas KL, Everitt BJ. Rapid and selective induction of BDNF expression in the hippocampus during contextual learning. Nature Neuroscience. 2000; 3: 533–535.
[63]
Duman RS, Monteggia LM. A Neurotrophic Model for Stress-Related Mood Disorders. Biological Psychiatry. 2006; 59: 1116–1127.
[64]
Autry AE, Monteggia LM. Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders. Pharmacological Reviews. 2012; 64: 238–258.
[65]
Park H, Poo M. Neurotrophin regulation of neural circuit development and function. Nature Reviews Neuroscience. 2013; 14: 7–23.
[66]
Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T, et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proceedings of the National Academy of Sciences. 2004; 101: 10827–10832.
[67]
Castrén E, Kojima M. Brain-derived neurotrophic factor in mood disorders and antidepressant treatments. Neurobiology of Disease. 2017; 97: 119–126.
[68]
Zaletel I, Filipović D, Puškaš N. Hippocampal BDNF in physiological conditions and social isolation. Reviews in the Neurosciences. 2017; 28: 675–692.
[69]
Björkholm C, Monteggia LM. BDNF – a key transducer of antidepressant effects. Neuropharmacology. 2016; 102: 72–79.
[70]
Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. The Lancet Psychiatry. 2017; 4: 409–418.
[71]
Kraus C, Castrén E, Kasper S, Lanzenberger R. Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression. Neuroscience and Biobehavioral Reviews. 2017; 77: 317–326.
[72]
Nibuya M, Morinobu S, Duman R. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. The Journal of Neuroscience. 1995; 15: 7539–7547.
[73]
Tyler WJ, Perrett SP, Pozzo-Miller LD. The Role of Neurotrophins in Neurotransmitter Release. The Neuroscientist. 2002; 8: 524–531.
[74]
Caldeira MV, Melo CV, Pereira DB, Carvalho R, Correia SS, Backos DS, et al. Brain-derived neurotrophic factor regulates the expression and synaptic delivery of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits in hippocampal neurons. The Journal of Biological Chemistry. 2007; 282: 12619–12628.
[75]
Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng P, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011; 475: 91–95.
[76]
Adachi M, Barrot M, Autry AE, Theobald D, Monteggia LM. Selective Loss of Brain-Derived Neurotrophic Factor in the Dentate Gyrus Attenuates Antidepressant Efficacy. Biological Psychiatry. 2008; 63: 642–649.
[77]
Magariños AM, McEwen BS. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: Comparison of stressors. Neuroscience. 1995; 69: 83–88.
[78]
Magariños AM, McEwen BS. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: Involvement of glucocorticoid secretion and excitatory amino acid receptors. Neuroscience. 1995; 69: 89–98.
[79]
Sheline YI, Liston C, McEwen BS. Parsing the Hippocampus in Depression: Chronic Stress, Hippocampal Volume, and Major Depressive Disorder. Biological Psychiatry. 2019; 85: 436–438.
[80]
Abdallah CG, Salas R, Jackowski A, Baldwin P, Sato JR, Mathew SJ. Hippocampal volume and the rapid antidepressant effect of ketamine. Journal of Psychopharmacology. 2015; 29: 591–595.
[81]
Spalding K, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner H, et al. Dynamics of Hippocampal Neurogenesis in Adult Humans. Cell. 2013; 153: 1219–1227.
[82]
Miller BR, Hen R. The current state of the neurogenic theory of depression and anxiety. Current Opinion in Neurobiology. 2015; 30: 51–58.
[83]
Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal Volume Reduction in Major Depression. American Journal of Psychiatry. 2000; 157: 115–118.
[84]
Frodl T, Schüle C, Schmitt G, Born C, Baghai T, Zill P, et al. Association of the Brain-Derived Neurotrophic Factor Val66Met Polymorphism with Reduced Hippocampal Volumes in Major Depression. Archives of General Psychiatry. 2007; 64: 410–416.
[85]
Huang Y, Coupland NJ, Lebel RM, Carter R, Seres P, Wilman AH, et al. Structural Changes in Hippocampal Subfields in Major Depressive Disorder: a High-Field Magnetic Resonance Imaging Study. Biological Psychiatry. 2013; 74: 62–68.
[86]
Wise T, Radua J, Via E, Cardoner N, Abe O, Adams TM, et al. Common and distinct patterns of grey-matter volume alteration in major depression and bipolar disorder: evidence from voxel-based meta-analysis. Molecular Psychiatry. 2017; 22: 1455–1463.
[87]
Alonso R, Griebel G, Pavone G, Stemmelin J, Le Fur G, Soubrié P. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Molecular Psychiatry. 2004; 9: 278–286.
[88]
Czéh B, Welt T, Fischer AK, Erhardt A, Schmitt W, Müller MB, et al. Chronic psychosocial stress and concomitant repetitive transcranial magnetic stimulation: effects on stress hormone levels and adult hippocampal neurogenesis. Biological Psychiatry. 2002; 52: 1057–1065.
[89]
Pham K, Nacher J, Hof PR, McEwen BS. Repeated restraint stress suppresses neurogenesis and induces biphasic PSA-NCAM expression in the adult rat dentate gyrus. European Journal of Neuroscience. 2003; 17: 879–886.
[90]
Micheli L, Ceccarelli M, D’Andrea G, Tirone F. Depression and adult neurogenesis: Positive effects of the antidepressant fluoxetine and of physical exercise. Brain Research Bulletin. 2018; 143: 181–193.
[91]
Yamada J, Jinno S. Potential link between antidepressant-like effects of ketamine and promotion of adult neurogenesis in the ventral hippocampus of mice. Neuropharmacology. 2019; 158: 107710.
[92]
Bannerman DM, Sprengel R, Sanderson DJ, McHugh SB, Rawlins JNP, Monyer H, et al. Hippocampal synaptic plasticity, spatial memory and anxiety. Nature Reviews Neuroscience. 2014; 15: 181–192.
[93]
Mastrodonato A, Martinez R, Pavlova IP, LaGamma CT, Brachman RA, Robison AJ, et al. Ventral CA3 Activation Mediates Prophylactic Ketamine Efficacy against Stress-Induced Depressive-like Behavior. Biological Psychiatry. 2018; 84: 846–856.
[94]
Carreno FR, Donegan JJ, Boley AM, Shah A, DeGuzman M, Frazer A, et al. Activation of a ventral hippocampus–medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine. Molecular Psychiatry. 2016; 21: 1298–1308.
[95]
Price RB, Duman R. Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model. Molecular Psychiatry. 2020; 25: 530–543.
[96]
Schmaal L, van Harmelen A, Chatzi V, Lippard ETC, Toenders YJ, Averill LA, et al. Imaging suicidal thoughts and behaviors: a comprehensive review of 2 decades of neuroimaging studies. Molecular Psychiatry. 2020; 25: 408–427.
[97]
Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biological Psychiatry. 1999; 45: 1085–1098.
[98]
Drevets WC. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Progress in Brain Research. 2000; 126: 413–431.
[99]
Kang HJ, Voleti B, Hajszan T, Rajkowska G, Stockmeier CA, Licznerski P, et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nature Medicine. 2012; 18: 1413–1417.
[100]
Deyama S, Kaneda K. The duration of the antidepressant-like effects of a single infusion of brain-derived neurotrophic factor into the medial prefrontal cortex in mice. Behavioural Brain Research. 2020; 394: 112844.
[101]
Oh H, Piantadosi SC, Rocco BR, Lewis DA, Watkins SC, Sibille E. The Role of Dendritic Brain-Derived Neurotrophic Factor Transcripts on Altered Inhibitory Circuitry in Depression. Biological Psychiatry. 2019; 85: 517–526.
[102]
Fukumoto K, Fogaça MV, Liu RJ, Duman C, Kato T, Li XY, et al. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine. Proceedings of the National Academy of Sciences of the United States of America. 2019; 116: 297–302.
[103]
Anderzhanova E, Hafner K, Genewsky AJ, Soliman A, Pöhlmann ML, Schmidt MV, et al. The stress susceptibility factor FKBP51 controls S-ketamine-evoked release of mBDNF in the prefrontal cortex of mice. Neurobiology of Stress. 2020; 13: 100239.
[104]
Lepack AE, Fuchikami M, Dwyer JM, Banasr M, Duman RS. BDNF Release is Required for the Behavioral Actions of Ketamine. International Journal of Neuropsychopharmacology. 2014; 18: pyu033.
[105]
Lett TA, Voineskos AN, Kennedy JL, Levine B, Daskalakis ZJ. Treating Working Memory Deficits in Schizophrenia: a Review of the Neurobiology. Biological Psychiatry. 2014; 75: 361–370.
[106]
Fortin DA, Srivastava T, Dwarakanath D, Pierre P, Nygaard S, Derkach VA, et al. Brain-Derived Neurotrophic Factor Activation of CaM-Kinase Kinase via Transient Receptor Potential Canonical Channels Induces the Translation and Synaptic Incorporation of GluA1-Containing Calcium-Permeable AMPA Receptors. Journal of Neuroscience. 2012; 32: 8127–8137.
[107]
Duman RS, Aghajanian GK. Synaptic Dysfunction in Depression: Potential Therapeutic Targets. Science. 2012; 338: 68–72.
[108]
Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010; 329: 959–964.
[109]
Radley JJ, Rocher AB, Miller M, Janssen WG, Liston C, Hof PR, et al. Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. Cerebral Cortex. 2006; 16: 313–320.
[110]
Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019; 364: eaat8078.
[111]
O’Donnell P, Grace AA. Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input. The Journal of Neuroscience. 1995; 15: 3622–3639.
[112]
Finch DM. Neurophysiology of converging synaptic inputs from the rat prefrontal cortex, amygdala, midline thalamus, and hippocampal formation onto single neurons of the caudate/putamen and nucleus accumbens. Hippocampus. 1996; 6: 495–512.
[113]
Mulder AB, Hodenpijl MG, Lopes da Silva FH. Electrophysiology of the Hippocampal and Amygdaloid Projections to the Nucleus Accumbens of the Rat: Convergence, Segregation, and Interaction of Inputs. The Journal of Neuroscience. 1998; 18: 5095–5102.
[114]
Hirayama K. Thalamus and Emotion. Brain and Nerve. 2015; 67: 1499–1508. (In Janpanese)
[115]
Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends in Neurosciences. 2007; 30: 194–202.
[116]
Castillo Díaz F, Caffino L, Fumagalli F. Bidirectional role of dopamine in learning and memory-active forgetting. Neuroscience and Biobehavioral Reviews. 2021; 131: 953–963.
[117]
French SJ, Totterdell S. Hippocampal and prefrontal cortical inputs monosynaptically converge with individual projection neurons of the nucleus accumbens. The Journal of Comparative Neurology. 2002; 446: 151–165.
[118]
Bagot RC, Parise EM, Peña CJ, Zhang H, Maze I, Chaudhury D, et al. Ventral hippocampal afferents to the nucleus accumbens regulate susceptibility to depression. Nature Communications. 2015; 6: 7062.
[119]
Goto Y, Grace AA. Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nature Neuroscience. 2005; 8: 805–812.
[120]
Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders [published correction appears in Nature Reviews Neuroscience. 2013; 14: 736]. Nature Reviews Neuroscience. 2013; 14: 609–625.
[121]
Berton O, McClung CA, DiLeone RJ, Krishnan V, Renthal W, Russo SJ, et al. Essential Role of BDNF in the Mesolimbic Dopamine Pathway in Social Defeat Stress. Science. 2006; 311: 864–868.
[122]
Chaudhury D, Walsh JJ, Friedman AK, Juarez B, Ku SM, Koo JW, et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature. 2013; 493: 532–536.
[123]
Walsh JJ, Friedman AK, Sun H, Heller EA, Ku SM, Juarez B, et al. Stress and CRF gate neural activation of BDNF in the mesolimbic reward pathway. Nature Neuroscience. 2014; 17: 27–29.
[124]
Wook Koo J, Labonté B, Engmann O, Calipari ES, Juarez B, Lorsch Z, et al. Essential Role of Mesolimbic Brain-Derived Neurotrophic Factor in Chronic Social Stress–Induced Depressive Behaviors. Biological Psychiatry. 2016; 80: 469–478.
[125]
Krishnan V, Han M, Graham DL, Berton O, Renthal W, Russo SJ, et al. Molecular Adaptations Underlying Susceptibility and Resistance to Social Defeat in Brain Reward Regions. Cell. 2007; 131: 391–404.
[126]
Eisch AJ, Bolaños CA, de Wit J, Simonak RD, Pudiak CM, Barrot M, et al. Brain-derived neurotrophic factor in the ventral midbrain–nucleus accumbens pathway: a role in depression. Biological Psychiatry. 2003; 54: 994–1005.
[127]
Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, et al. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology. 1998; 37: 1–12.
[128]
Witkin JM, Monn JA, Schoepp DD, Li X, Overshiner C, Mitchell SN, et al. The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits. Journal of Pharmacology and Experimental Therapeutics. 2016; 358: 71–82.
[129]
Strous JFM, Weeland CJ, van der Draai FA, Daams JG, Denys D, Lok A, et al. Brain Changes Associated With Long-Term Ketamine Abuse, A Systematic Review. Frontiers in Neuroanatomy. 2022; 16: 795231.
[130]
Can A, Zanos P, Moaddel R, Kang HJ, Dossou KSS, Wainer IW, et al. Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters. Journal of Pharmacology and Experimental Therapeutics. 2016; 359: 159–170.
[131]
Aleksandrova LR, Wang YT, Phillips AG. Evaluation of the Wistar-Kyoto rat model of depression and the role of synaptic plasticity in depression and antidepressant response. Neuroscience and Biobehavioral Reviews. 2019; 105: 1–23.
[132]
Aleksandrova LR, Wang YT, Phillips AG. Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression. Molecular Brain. 2020; 13: 92.
[133]
Carboni E, Silvagni A. Experimental Investigations on Dopamine Transmission can Provide Clues on the Mechanism of the Therapeutic Effect of Amphetamine and Methylphenidate in ADHD. Neural Plasticity. 2004; 11: 77–95.
[134]
Belujon P, Grace AA. Restoring Mood Balance in Depression: Ketamine Reverses Deficit in Dopamine-Dependent Synaptic Plasticity. Biological Psychiatry. 2014; 76: 927–936.
[135]
Yao N, Skiteva O, Zhang X, Svenningsson P, Chergui K. Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit. Molecular Psychiatry. 2018; 23: 2066–2077.
[136]
Réus GZ, Stringari RB, Ribeiro KF, Ferraro AK, Vitto MF, Cesconetto P, et al. Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behavioural Brain Research. 2011; 221: 166–171.
[137]
Abdallah CG, Jackowski A, Salas R, Gupta S, Sato JR, Mao X, et al. The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder. Neuropsychopharmacology. 2017; 42: 1739–1746.
[138]
Matsumoto M, Hikosaka O. Lateral habenula as a source of negative reward signals in dopamine neurons. Nature. 2007; 447: 1111–1115.
[139]
Li K, Zhou T, Liao L, Yang Z, Wong C, Henn F, et al. βCaMKII in lateral habenula mediates core symptoms of depression. Science. 2013; 341: 1016–1020.
[140]
Proulx CD, Hikosaka O, Malinow R. Reward processing by the lateral habenula in normal and depressive behaviors. Nature Neuroscience. 2014; 17: 1146–1152.
[141]
Gold PW, Kadriu B. A Major Role for the Lateral Habenula in Depressive Illness: Physiologic and Molecular Mechanisms. Frontiers in Psychiatry. 2019; 10: 320.
[142]
Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018; 554: 317–322.
[143]
Shabel SJ, Wang C, Monk B, Aronson S, Malinow R. Stress transforms lateral habenula reward responses into punishment signals. Proceedings of the National Academy of Sciences. 2019; 116: 12488–12493.
[144]
Browne CA, Hammack R, Lucki I. Dysregulation of the Lateral Habenula in Major Depressive Disorder. Frontiers in Synaptic Neuroscience. 2018; 10: 46.
[145]
Hikosaka O. The habenula: from stress evasion to value-based decision-making. Nature Reviews Neuroscience. 2010; 11: 503–513.
[146]
Kim U, Lee T. Topography of descending projections from anterior insular and medial prefrontal regions to the lateral habenula of the epithalamus in the rat. European Journal of Neuroscience. 2012; 35: 1253–1269.
[147]
Shepard RD, Langlois LD, Browne CA, Berenji A, Lucki I, Nugent FS. Ketamine Reverses Lateral Habenula Neuronal Dysfunction and Behavioral Immobility in the Forced Swim Test Following Maternal Deprivation in Late Adolescent Rats. Frontiers in Synaptic Neuroscience. 2018; 10: 39.
[148]
Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S. Distribution of Brain-Derived Neurotrophic Factor (BDNF) Protein and mRNA in the Normal Adult Rat CNS: Evidence for Anterograde Axonal Transport. The Journal of Neuroscience. 1997; 17: 2295–2313.
[149]
Lei T, Dong D, Song M, Sun Y, Liu X, Zhao H. Rislenemdaz treatment in the lateral habenula improves despair-like behavior in mice. Neuropsychopharmacology. 2020; 45: 1717–1724.
[150]
Berghauzen-Maciejewska K, Wardas J, Kosmowska B, Głowacka U, Kuter K, Ossowska K. Alterations of BDNF and trkB mRNA expression in the 6-hydroxydopamine-induced model of preclinical stages of Parkinson’s disease: an influence of chronic pramipexole in rats. PLoS ONE. 2015; 10: e0117698.
[151]
Wang Y, Qu P, Sun Y, Li Z, Liu L, Yang L. Association between increased inflammatory cytokine expression in the lateral habenular nucleus and depressive-like behavior induced by unpredictable chronic stress in rats. Experimental Neurology. 2022; 349: 113964.
[152]
Cui Y, Hu S, Hu H. Lateral Habenular Burst Firing as a Target of the Rapid Antidepressant Effects of Ketamine. Trends in Neurosciences. 2019; 42: 179–191.
[153]
Carlsen J. Immunocytochemical localization of glutamate decarboxylase in the rat basolateral amygdaloid nucleus, with special reference to GABAergic innervation of amygdalostriatal projection neurons. The Journal of Comparative Neurology. 1988; 273: 513–526.
[154]
McDonald AJ. Cytoarchitecture of the central amygdaloid nucleus of the rat. The Journal of Comparative Neurology. 1982; 208: 401–418.
[155]
McDonald AJ. Glutamate and aspartate immunoreactive neurons of the rat basolateral amygdala: Colocalization of excitatory amino acids and projections to the limbic circuit. The Journal of Comparative Neurology. 1996; 365: 367–379.
[156]
Zhang J, Liu T, He Y, Pan H, Zhang W, Yin X, et al. Chronic Stress Remodels Synapses in an Amygdala Circuit–Specific Manner. Biological Psychiatry. 2019; 85: 189–201.
[157]
Vyas A, Jadhav S, Chattarji S. Prolonged behavioral stress enhances synaptic connectivity in the basolateral amygdala. Neuroscience. 2006; 143: 387–393.
[158]
Bennett MR, Lagopoulos J. Stress and trauma: BDNF control of dendritic-spine formation and regression. Progress in Neurobiology. 2014; 112: 80–99.
[159]
Duman CH, Duman RS. Spine synapse remodeling in the pathophysiology and treatment of depression. Neuroscience Letters. 2015; 601: 20–29.
[160]
Mayberg HS. Targeted electrode-based modulation of neural circuits for depression. Journal of Clinical Investigation. 2009; 119: 717–725.
[161]
Savitz J, Drevets WC. Bipolar and major depressive disorder: Neuroimaging the developmental-degenerative divide. Neuroscience and Biobehavioral Reviews. 2009; 33: 699–771.
[162]
Vidal-Gonzalez I, Vidal-Gonzalez B, Rauch SL, Quirk GJ. Microstimulation reveals opposing influences of prelimbic and infralimbic cortex on the expression of conditioned fear. Learning and Memory. 2006; 13: 728–733.
[163]
Asim M, Hao B, Yang Y, Fan B, Xue L, Shi Y, et al. Ketamine Alleviates Fear Generalization through GluN2B-BDNF Signaling in Mice. Neuroscience Bulletin. 2020; 36: 153–164.
[164]
Karolewicz B, Szebeni K, Gilmore T, Maciag D, Stockmeier CA, Ordway GA. Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. The International Journal of Neuropsychopharmacology. 2009; 12: 143.
[165]
Sterrenburg L, Gaszner B, Boerrigter J, Santbergen L, Bramini M, Elliott E, et al. Chronic stress induces sex-specific alterations in methylation and expression of corticotropin-releasing factor gene in the rat. PLoS ONE. 2011; 6: e28128.
[166]
Renthal W, Maze I, Krishnan V, Covington HE, Xiao G, Kumar A, et al. Histone Deacetylase 5 Epigenetically Controls Behavioral Adaptations to Chronic Emotional Stimuli. Neuron. 2007; 56: 517–529.
[167]
Covington HE, Vialou VF, LaPlant Q, Ohnishi YN, Nestler EJ. Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition. Neuroscience Letters. 2011; 493: 122–126.
[168]
Hollis F, Duclot F, Gunjan A, Kabbaj M. Individual differences in the effect of social defeat on anhedonia and histone acetylation in the rat hippocampus. Hormones and Behavior. 2011; 59: 331–337.
[169]
Davis M, Walker DL, Miles L, Grillon C. Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety. Neuropsychopharmacology. 2010; 35: 105–135.
[170]
Kim S, Adhikari A, Lee SY, Marshel JH, Kim CK, Mallory CS, et al. Diverging neural pathways assemble a behavioural state from separable features in anxiety. Nature. 2013; 496: 219–223.
[171]
Jennings JH, Sparta DR, Stamatakis AM, Ung RL, Pleil KE, Kash TL, et al. Distinct extended amygdala circuits for divergent motivational states. Nature. 2013; 496: 224–228.
[172]
Walker DL, Toufexis DJ, Davis M. Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. European Journal of Pharmacology. 2003; 463: 199–216.
[173]
Sahuque LL, Kullberg EF, Mcgeehan AJ, Kinder JR, Hicks MP, Blanton MG, et al. Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: role of CRF receptor subtypes. Psychopharmacology. 2006; 186: 122–132.
[174]
Choi DC, Evanson NK, Furay AR, Ulrich-Lai YM, Ostrander MM, Herman JP. The Anteroventral Bed Nucleus of the Stria Terminalis Differentially Regulates Hypothalamic-Pituitary-Adrenocortical Axis Responses to Acute and Chronic Stress. Endocrinology. 2008; 149: 818–826.
[175]
Hammack SE, Braas KM, May V. Chemoarchitecture of the bed nucleus of the stria terminalis: Neurophenotypic diversity and function. Handbook of Clinical Neurology. 2021; 179: 385–402.
[176]
Alheid GF, Beltramino CA, de Olmos JS, Forbes MS, Swanson DJ, Heimer L. The neuronal organization of the supracapsular part of the stria terminalis in the rat: the dorsal component of the extended amygdala. Neuroscience. 1998; 84: 967–996.
[177]
Cadeddu R, Ibba M, Sadile A, Carboni E. Antidepressants share the ability to increase catecholamine output in the bed nucleus of stria terminalis: a possible role in antidepressant therapy? Psychopharmacology. 2014; 231: 1925–1933.
[178]
Linley SB, Olucha-Bordonau F, Vertes RP. Pattern of distribution of serotonergic fibers to the amygdala and extended amygdala in the rat. Journal of Comparative Neurology. 2017; 525: 116–139.
[179]
Awasthi JR, Tamada K, Overton ETN, Takumi T. Comprehensive topographical map of the serotonergic fibers in the male mouse brain. Journal of Comparative Neurology. 2021; 529: 1391–1429.
[180]
Oler JA, Fox AS, Shelton SE, Christian BT, Murali D, Oakes TR, et al. Serotonin Transporter Availability in the Amygdala and Bed Nucleus of the Stria Terminalis Predicts Anxious Temperament and Brain Glucose Metabolic Activity. Journal of Neuroscience. 2009; 29: 9961–9966.
[181]
Myers B, Mark Dolgas C, Kasckow J, Cullinan WE, Herman JP. Central stress-integrative circuits: forebrain glutamatergic and GABAergic projections to the dorsomedial hypothalamus, medial preoptic area, and bed nucleus of the stria terminalis. Brain Structure and Function. 2014; 219: 1287–1303.
[182]
Aston-jones G, Delfs JM, Druhan J, Zhu Y. The Bed Nucleus of the Stria Terminalis: a Target Site for Noradrenergic Actions in Opiate Withdrawal. Annals of the New York Academy of Sciences. 1999; 877: 486–498.
[183]
Delfs JM, Zhu Y, Druhan JP, Aston-Jones G. Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature. 2000; 403: 430–434.
[184]
Forray MI, Bustos G, Gysling K. Regulation of norepinephrine release from the rat bed nucleus of the stria terminalis: in vivo microdialysis studies. Journal of Neuroscience Research. 1997; 50: 1040–1046.
[185]
Herman JP, Katz LN, Krauzlis RJ. Midbrain activity can explain perceptual decisions during an attention task [published correction appears in Nature Neuroscience. 2019; 22: 504]. Nature Neuroscience. 2018; 21: 1651–1655.
[186]
Phelix CF, Liposits Z, Paull WK. Monoamine innervation of bed nucleus of stria terminalis: an electron microscopic investigation. Brain Research Bulletin. 1992; 28: 949–965.
[187]
Carboni E, Silvagni A, Rolando MT, Di Chiara G. Stimulation of in vivo dopamine transmission in the bed nucleus of stria terminalis by reinforcing drugs. The Journal of Neuroscience. 2000; 20: RC102.
[188]
Jadzic D, Bassareo V, Carta AR, Carboni E. Nicotine, cocaine, amphetamine, morphine, and ethanol increase norepinephrine output in the bed nucleus of stria terminalis of freely moving rats. Addiction Biology. 2021; 26: e12864.
[189]
Erb S, Shaham Y, Stewart J. Stress-induced Relapse to Drug Seeking in the Rat; Role of the Bed Nucleus of the Stria Terminalis and Amygdala. Stress. 2001; 4: 289–303.
[190]
Kudo T, Uchigashima M, Miyazaki T, Konno K, Yamasaki M, Yanagawa Y, et al. Three Types of Neurochemical Projection from the Bed Nucleus of the Stria Terminalis to the Ventral Tegmental Area in Adult Mice. Journal of Neuroscience. 2012; 32: 18035–18046.
[191]
Silberman Y, Winder DG. Emerging role for corticotropin releasing factor signaling in the bed nucleus of the stria terminalis at the intersection of stress and reward. Frontiers in Psychiatry. 2013; 4: 42.
[192]
Georges F, Aston-Jones G. Potent Regulation of Midbrain Dopamine Neurons by the Bed Nucleus of the Stria Terminalis. The Journal of Neuroscience. 2001; 21: RC160.
[193]
Hara R, Takahashi D, Takehara T, Amano T, Minami M. Inhibitory synaptic transmissions to the bed nucleus of the stria terminalis neurons projecting to the ventral tegmental area are enhanced in rats exposed to chronic mild stress. Molecular Brain. 2020; 13: 139.
[194]
Ju G, Han Z. Coexistence of corticotropin releasing factor and neurotensin within oval nucleus neurons in the bed nuclei of the stria terminalis in the rat. Neuroscience Letters. 1989; 99: 246–250.
[195]
Dong H, Petrovich GD, Swanson LW. Topography of projections from amygdala to bed nuclei of the stria terminalis. Brain Research Reviews. 2001; 38: 192–246.
[196]
Dong H, Petrovich GD, Watts AG, Swanson LW. Basic organization of projections from the oval and fusiform nuclei of the bed nuclei of the stria terminalis in adult rat brain. The Journal of Comparative Neurology. 2001; 436: 430–455.
[197]
Sparta DR, Jennings JH, Ung RL, Stuber GD. Optogenetic strategies to investigate neural circuitry engaged by stress. Behavioural Brain Research. 2013; 255: 19–25.
[198]
Fitzgerald PB, Segrave R, Richardson KE, Knox LA, Herring S, Daskalakis ZJ, et al. A pilot study of bed nucleus of the stria terminalis deep brain stimulation in treatment-resistant depression. Brain Stimulation. 2018; 11: 921–928.
[199]
Hu P, Maita I, Phan ML, Gu E, Kwok C, Dieterich A, et al. Early-life stress alters affective behaviors in adult mice through persistent activation of CRH-BDNF signaling in the oval bed nucleus of the stria terminalis. Translational Psychiatry. 2020; 10: 396.
[200]
Liu W, Wang J, Xie Z, Xu N, Zhang G, Jia M, et al. Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression. Psychopharmacology. 2016; 233: 405–415.
[201]
Nutt DJ. The neuropharmacology of serotonin and noradrenaline in depression. International Clinical Psychopharmacology. 2002; 17: S1–S12.
[202]
Musazzi L, Tornese P, Sala N, Popoli M. Acute or Chronic? A Stressful Question. Trends in Neurosciences. 2017; 40: 525–535.
[203]
Carboni E, Barros VG, Ibba M, Silvagni A, Mura C, Antonelli MC. Prenatal restraint stress: an in vivo microdialysis study on catecholamine release in the rat prefrontal cortex. Neuroscience. 2010; 168: 156–166.
[204]
Maglanoc LA, Kaufmann T, Jonassen R, Hilland E, Beck D, Landrø NI, et al. Multimodal fusion of structural and functional brain imaging in depression using linked independent component analysis. Human Brain Mapping. 2020; 41: 241–255.
[205]
Gong J, Wang J, Qiu S, Chen P, Luo Z, Wang J, et al. Common and distinct patterns of intrinsic brain activity alterations in major depression and bipolar disorder: voxel-based meta-analysis. Translational Psychiatry. 2020; 10: 353.
[206]
Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain, Behavior, and Immunity. 2019; 81: 24–40.
[207]
Ménard C, Hodes GE, Russo SJ. Pathogenesis of depression: Insights from human and rodent studies. Neuroscience. 2016; 321: 138–162.
[208]
Villas Boas GR, Boerngen de Lacerda R, Paes MM, Gubert P, Almeida WLDC, Rescia VC, et al. Molecular aspects of depression: A review from neurobiology to treatment. European Journal of Pharmacology. 2019; 851: 99–121.
[209]
Anacker C, Luna VM, Stevens GS, Millette A, Shores R, Jimenez JC, et al. Hippocampal neurogenesis confers stress resilience by inhibiting the ventral dentate gyrus. Nature. 2018; 559: 98–102.
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Share
Back to top